{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:31Z","timestamp":1791355771944,"version":"4.3.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Acute limb ischemia (ALI) is both limb- and life-threatening, and represents a vascular emergency. Malignancy produces a systemic hypercoagulable state that predisposes to arterial as well as venous thrombosis, and poly(ADP-ribose) polymerase (PARP) inhibitors\u2014now central to maintenance therapy in ovarian cancer\u2014have, in aggregate randomized data, been associated with only a borderline venous signal and no clearly demonstrated independent arterial signal. We report a 60-year-old woman with active high-grade serous ovarian carcinoma maintained on oral fuzuloparib who presented with Rutherford category IIa ALI of the right lower limb on a background of chronic bilateral atherosclerosis. Angiography demonstrated occlusion of the right common iliac\u2013external iliac\u2013common femoral\u2013proximal superficial femoral segment with collateral reconstitution and, after dedicated cardiac evaluation (regular sinus rhythm on ECG, no arrhythmia on perioperative telemetry, normal transthoracic echocardiography without intracardiac thrombus or vegetation, and no critical carotid stenosis), no identifiable cardioembolic source. A single-stage hybrid procedure\u2014open common femoral thromboembolectomy followed by contralateral (crossover) endovascular treatment of a residual flow-limiting dissection with overlapping self-expanding and balloon-expandable covered stents\u2014restored inline flow and salvaged the limb; the retrieved material was submitted for histopathology, which demonstrated bland fibrin\u2013platelet\u2013red-cell thrombus with lines of Zahn and negative AE1\/AE3 immunostaining, excluding tumour embolism. The patient was transitioned to therapeutic anticoagulation within a multidisciplinary framework, and at 3 months the limb remained viable with palpable distal pulses. This case illustrates cancer-associated arterial thrombosis superimposed on atherosclerosis\u2014on a background that also included PARP-inhibitor exposure, whose independent contribution remains speculative\u2014highlights a hybrid open\u2013endovascular strategy for definitive single-setting revascularization, and underscores the importance of excluding a cardioembolic source and confirming thrombus nature histologically, while individualizing long-term anticoagulation that is necessarily extrapolated from cancer-associated venous thromboembolism evidence, with attention to drug\u2013drug interactions, thrombocytopenia and bleeding risk.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1916588","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:31Z","timestamp":1791352231000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hybrid surgical thromboembolectomy and crossover endovascular revascularization for acute lower-limb ischemia in a patient with active ovarian cancer receiving a PARP inhibitor (fuzuloparib): a case report and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"Yibiao","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Wound and Peripheral Vascular Surgery, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Wound and Peripheral Vascular Surgery, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Wound and Peripheral Vascular Surgery, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Wound and Peripheral Vascular Surgery, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Wound and Peripheral Vascular Surgery, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","place":["Tianjin, China"]},{"name":"National Clinical Research Center for Chinese Medicine","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","article-title":"Editor\u2019s choice \u2014 european society for vascular surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia","volume":"59","author":"Bj\u00f6rck","year":"2020","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for reports dealing with lower extremity ischemia: revised version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J Vasc Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1056\/NEJMcp1006054","article-title":"Acute limb ischemia","volume":"366","author":"Creager","year":"2012","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.jvs.2021.03.058","article-title":"A systematic review and meta-analysis of outcomes after acute limb ischemia in patients with cancer","volume":"74","author":"Govsyeyev","year":"2021","journal-title":"J Vasc Surg"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jtha.2023.02.029","article-title":"Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity","volume":"21","author":"Falanga","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11936-018-0635-x","article-title":"Arterial thrombosis in patients with cancer","volume":"20","author":"Tuzovic","year":"2018","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3324\/haematol.2018.192419","article-title":"Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer","volume":"103","author":"Grilz","year":"2018","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"105811","DOI":"10.1016\/j.esmoop.2025.105811","article-title":"Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis","volume":"10","author":"Yazgan","year":"2025","journal-title":"ESMO Open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s12094-025-04048-z","article-title":"SEOM thrombosis and cancer group. PARP inhibitors-associated thrombosis in patients with ovarian cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group","volume":"28","author":"S\u00e1nchez C\u00e1novas","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.3802\/jgo.2022.33.e86","article-title":"Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective","volume":"33","author":"Li","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70042","DOI":"10.3322\/caac.70042","article-title":"Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): a multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"76","author":"Wu","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B15","doi-asserted-by":"publisher","first-page":"853211","DOI":"10.3389\/fonc.2022.853211","article-title":"Case report: niraparib-related pulmonary embolism during the treatment of BRCA mutant advanced ovarian cancer","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: aSCO clinical practice guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT)","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism (hokusai VTE cancer)","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor xa inhibitor with low-molecular-weight heparin in patients with cancer with venous thromboembolism (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer (caravaggio)","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle\u2013brachial index: a scientific statement from the American Heart Association","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: jACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.6004\/jnccn.2021.0047","article-title":"Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Streiff","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B27","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue factor: an essential mediator of hemostasis and trigger of thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/15266028241255544","article-title":"Mid-term outcomes of image-guided surgical thromboembolectomy and routine intraoperative angiography for native-vessel acute lower-limb-threatening ischaemia","volume":"33","author":"Taha","year":"2024","journal-title":"J Endovasc Ther"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3390\/cancers16122238","article-title":"Arterial thrombosis in patients with cancer","volume":"16","author":"Xu","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102393","DOI":"10.1016\/j.rpth.2024.102393","article-title":"Cancer and arterial thrombosis: therapeutic options","volume":"8","author":"Cheong","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.acvd.2023.11.007","article-title":"Cancer-related arterial thromboembolic events","volume":"117","author":"Pernod","year":"2024","journal-title":"Arch Cardiovasc Dis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1916588\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:33Z","timestamp":1791352233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1916588\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2026.1916588"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1916588","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1916588"}}